Clarissa Drogosch
Family · Lawrenceville, GANPI 1598463549
Payments from drug & device makers
Across 264 payments — averaging $25.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$761
- Tandem Diabetes Care, Inc.$655
- Amgen$378
- Dexcom, Inc.$349
- Sanofi-aventis U.S. LLC$307
- plus $3K from 30 others
What the payments were for
- Food & beverage$6,648100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 49 | $1,163 |
| Lilly USA, LLC | 37 | $761 |
| Tandem Diabetes Care, Inc. | 17 | $655 |
| Amgen(2 entities) | 13 | $378 |
| Dexcom, Inc. | 7 | $349 |
| Sanofi-aventis U.S. LLC | 18 | $307 |
| Insulet Corporation | 7 | $289 |
| BETA Bionics, Inc. | 6 | $247 |
| Corcept Therapeutics | 15 | $242 |
| Abbott | 5 | $241 |
| Xeris Pharmaceuticals, Inc. | 13 | $240 |
| Radius Health, Inc. | 9 | $203 |
| Sequel Med Tech, LLC | 2 | $183 |
| Madrigal Pharmaceuticals | 3 | $182 |
| Averitas Pharma Inc. | 2 | $162 |
| Mannkind Corporation | 5 | $106 |
| Amneal Pharmaceuticals LLC | 6 | $101 |
| Ascensia Diabetes Care US Inc. | 5 | $84 |
| AbbVie | 5 | $80 |
| Boehringer Ingelheim | 4 | $80 |
| Bayer | 5 | $77 |
| Embecta Corp. | 4 | $77 |
| AstraZeneca | 4 | $62 |
| Amphastar Pharmaceuticals, Inc. | 3 | $54 |
| Kyowa Kirin, Inc. | 3 | $53 |
| Verity Pharmaceuticals Inc. | 3 | $51 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $45 |
| Ascendis Pharma Endocrinology Inc | 1 | $29 |
| Acella Pharmaceuticals, LLC | 2 | $27 |
| Amryt Pharma Holdings Ltd | 2 | $27 |
| Cequr Corporation | 1 | $26 |
| Astellas Pharma US Inc | 1 | $18 |
| Theracosbio, LLC | 2 | $17 |
| Nevro Corp. | 1 | $15 |
| Silk Road Medical, Inc. | 1 | $14 |
| Ionis Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t:slim X2 Insulin Pump with Control-IQ$467
- iLet Bionic Pancreas$430
- DEXCOM G6 TRANSMITTER$236
- Omnipod$169
- FREESTYLE LIBRE 3$164
- TWIIST$158
- Qutenza$147
- REZDIFFRA$140
- TEPEZZA$134
- Wegovy$122
- Ozempic$101
How this compares
$6,660 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 315 | $527,752 |
| JardianceEmpagliflozin | 208 | $303,083 |
| MounjaroTirzepatide | 149 | $225,851 |
| TrulicityDulaglutide | 99 | $156,725 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 66 | $131,534 |
| Tresiba Flextouch U-100Insulin Degludec | 116 | $103,547 |
| FarxigaDapagliflozin Propanediol | 61 | $71,629 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $59,876 |
| JanuviaSitagliptin Phosphate | 39 | $54,238 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 28 | $53,330 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $47,241 |
| Novolog FlexpenInsulin Aspart | 104 | $41,380 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 19 | $34,175 |
| Humalog Kwikpen U-100Insulin Lispro | 59 | $32,474 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 231 | $32,381 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,163 | $576,602382 claims |
| Lilly USA, LLCMounjaro, Trulicity, Baqsimi, Humalog | $761 | $391,635279 claims |
| Boehringer IngelheimJardiance, Tradjenta | $80 | $331,826246 claims |
| AstraZenecaFarxiga | $62 | $71,62961 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $307 | $30,02838 claims |
| AbbVieSynthroid | $80 | $3,28528 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $101 | $2,587246 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.
Other family in Lawrenceville
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Jennifer BlackLawrenceville$19K
- Ashley BeikmannLawrenceville$16K
- Allie McAllisterMarietta$299K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.